1. TRAIL-coated lipid-nanoparticles overcome resistance to soluble recombinant TRAIL in non-small cell lung cancer cells
   Diego De Miguel et al, 2016, Nanotechnology CrossRef
2. Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 Is Generally Well-Tolerated and Has Activity in Non–Small-Cell Lung Cancer and Other Solid Tumors: Results of a Phase I Trial
   Roy S. Herbst et al, 2002, JCO CrossRef
3. Phase I/II Trial Evaluating the Anti-Vascular Endothelial Growth Factor Monoclonal Antibody Bevacizumab in Combination With the HER-1/Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib for Patients With Recurrent Non–Small-Cell Lung Cancer
   Roy S. Herbst et al, 2005, JCO CrossRef
4. Epidermal Growth Factor Receptor Mutations in Non–Small-Cell Lung Cancer: Implications for Treatment and Tumor Biology
   Pasi A. Jänne et al, 2005, JCO CrossRef
5. Challenges and Perspectives on the Development of Small-Molecule EGFR Inhibitors against T790M-Mediated Resistance in Non-Small-Cell Lung Cancer
   Zhendong Song et al, 2016, J. Med. Chem. CrossRef
6. Receptor Imaging in Oncology by Means of Nuclear Medicine: Current Status
   Bieke Van Den Bossche et al, 2004, JCO CrossRef
7. HER1/EGFR-targeted agents: predicting the future for patients with unpredictable outcomes to therapy
   G. Giaccone, 2005 CrossRef
8. Gossypol Inhibits Non-small Cell Lung Cancer Cells Proliferation by Targeting EGFRL858R/T790M
   Yuwei Wang et al, 2018, Front. Pharmacol. CrossRef
9. Significance of EGFR Protein Expression and Gene Amplification in Non–Small Cell Lung Carcinoma
   Sanja Dacic et al, 2006, Am J Clin Pathol CrossRef
10. Prognostic Impact of Melatonin Receptors MT1 and MT2 in Non-Small Cell Lung Cancer (NSCLC)
    null Jablonska et al, 2019, Cancers CrossRef
11. Synergistic Occurrence of EGFR, ALK, and KRAS Gene Mutations in a Patient with Non-small Cell Lung Cancer (Adenocarcinoma)
    Dinesh Chandra Doval et al, 2019, IJMS CrossRef
12. Targeting Cancer Resistance via Multifunctional Gold Nanoparticles
    Pedro Pedrosa et al, 2019, IJMS CrossRef
13. Epidermal Growth Factor Receptor in Non–Small-Cell Lung Carcinomas: Correlation Between Gene Copy Number and Protein Expression and Impact on Prognosis
    Fred R. Hirsch et al, 2003, JCO CrossRef
14. Comparison of the characteristics of uncommon epidermal growth factor receptor (EGFR) mutations and EGFR‑tyrosine kinase inhibitor treatment in patients with non‑small cell lung cancer from different ethnic groups
    Qiao Zhang et al, 2020, Exp Ther Med CrossRef
15. Humoral immune response to epidermal growth factor receptor in lung cancer
    Yulin Wang et al, 2021, Immunol Res CrossRef
16. Studies in Lung cancer cytokine proteomics: A review
    Hanieh Abolfathi et al, 2021, Expert Review of Proteomics CrossRef
17. HER2-/HER3-Targeting Antibody—Drug Conjugates for Treating Lung and Colorectal Cancers Resistant to EGFR Inhibitors
    Kimio Yonesaka, 2021, Cancers CrossRef
18. Epidermal Growth Factor Receptor Expression and Resistance Patterns to Targeted Therapy in Non-Small Cell Lung Cancer: A Review
    Emma-Anne Karlsen et al, 2021, Cells CrossRef
19. Study of Programmed Death Ligand 1 and EGFR/HER2 Expression in Non-Small-Cell Lung Carcinoma With a Clinicopathological Spectrum
    Devina Laishram et al, 2021 CrossRef
20. In Silico Anticancer Evaluation, Molecular Docking and Pharmacophore Modeling of Flavonoids against Various Cancer Targets
    Jainey Puthenveettil James et al, 2020, LDDD CrossRef
21. Synergistic Antitumor Activity of SH003 and Docetaxel via EGFR Signaling Inhibition in Non-Small Cell Lung Cancer
    Mi-So Jeong et al, 2021, IJMS CrossRef
22. Deciphering the Mechanism of Binding Selectivity of Chlorofluoroacetamide-Based Covalent Inhibitors toward L858R/T790M Resistance Mutation
    Farideh Badichi Akher et al, 2022, J. Chem. Inf. Model. CrossRef
23. Targeting of AKT1 enhances radiation toxicity of human tumor cells by inhibiting DNA-PKcs-dependent DNA double-strand break repair
    Mahmoud Toulany et al, 2008 CrossRef
24. A Phase II Study of Gefitinib Monotherapy in Advanced Esophageal Adenocarcinoma: Evidence of Gene Expression, Cellular, and Clinical Response
    David R. Ferry et al, 2007 CrossRef
25. Autocrine Production of Amphiregulin Predicts Sensitivity to Both Gefitinib and Cetuximab in EGFR Wild-type Cancers
    Kimio Yonesaka et al, 2008 CrossRef
26. The Role of Gefitinib in Lung Cancer Treatment
    Giuseppe Giaccone, 2004 CrossRef
27. Multifunctional Oxygenated Particles for Targeted Cancer Drug Delivery and Evaluation with Darkfield Hyperspectral Imaging
    Yi Wen et al, 2022, ACS Omega CrossRef
28. null
    Mansi K. Aparnathi et al, 2022 CrossRef
29. null
    Md Abedul Haque, 2023 CrossRef
30. EGFR is a potential dual molecular target for cancer and Alzheimer’s disease
    Hee-Jeong Choi et al, 2023, Front. Pharmacol. CrossRef
31. Kernel-based prediction of a synergistic drug combination
    Jun ZHANG et al, 2023, Sci. Sin.-Vitae CrossRef
32. In Vitro and In Silico Studies on 4-Nitroacetophenone Thiosemicarbazone Potential Cytotoxicity Against A549 Cell Lines
    Neha Verma et al, 2023, Appl Biochem Biotechnol CrossRef
33. Alkaloids from Zanthoxylum nitidum and their anti-proliferative activity against A549 cells by regulating the EGFR/AKT/mTOR pathway
    Fan-Fan Wang et al, 2024, Natural Product Research CrossRef
34. Application of Epithelial Growth Factor Receptor-Targeted Magnetic Resonance Imaging and Near-Infrared II Dual-Modal Probe in Lung Cancer Diagnosis and Surgical Resection
    Chao Li et al, 2024, Mol. Pharmaceutics CrossRef
35. Identification of potential inhibitors for drug-resistant EGFR mutations in non-small cell lung cancer using whole exome sequencing data
    Nagasundaram Nagarajan et al, 2024, Front. Pharmacol. CrossRef